Evidence map›Paper›PMID 34003366›Full record

ArticleJournal of cancer research and clinical oncology2021

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.

Anna Ianza, A Di Chicco, C Biagi, F Giudici, A Dicorato, A Guglielmi, F Variola, S Tomasi, G Roviello, D Generali and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 citations in OpenAlex.

  1. Mutation-Specific Response to Ramucirumab inJTO clinical and research reports · 2026
    Article
  2. Article
  3. Importance ofCancer drug resistance (Alhambra, Calif.) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Anna IanzaDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy. annaianzamiccoli@gmail.com.ORCID http://orcid.org/0000-0002-3527-8040
A Di ChiccoDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
C BiagiAzienda Sanitaria Universitaria Goriziano Isontina, Cattinara Academic Hospital, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.
F GiudiciDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
A DicoratoAzienda Sanitaria Universitaria Goriziano Isontina, Cattinara Academic Hospital, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.
A GuglielmiAzienda Sanitaria Universitaria Goriziano Isontina, Cattinara Academic Hospital, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.
F VariolaAzienda Sanitaria Universitaria Goriziano Isontina, Cattinara Academic Hospital, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.
S TomasiAzienda Sanitaria Universitaria Goriziano Isontina, Cattinara Academic Hospital, University of Trieste, Strada di Fiume 447, 34149, Trieste, Italy.
G RovielloDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
D GeneraliDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
F ZanconatiDepartment of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.
University of Trieste · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeMonitoring mutation status in circulating free DNA (cfDNA) during target therapy could hold significant clinical importance in non-small cell lung cancer (NSCLC). Our aim is to establish if EGFR mutational status change on cfDNA has predictive value that can impact clinical management of NSCLC patients care.

methodsThis study included 30 patients with EGFR-mutated NSCLC. Blood samples were collected at diagnosis (T0) and in 19 patients during therapy (T1).

resultsConcordance between T0 and T1 EGFR mutation status for patients evaluable for both samples (n = 19) was 79%, with a sensitivity of 100% (95% CI: 55.5-100.0) and specificity of 60.0% (95% CI: 26.2-86.8). For the patients in oncological therapy with targeted drug and with T1 sample available (n = 18), survival outcomes were evaluated. For both mutation-negative T0 and T1 patients, 12-month progression-free survival (PFS) was 66.7% (95% CI: 27.2-100.0) and 12-month overall survival (OS) was 100% (95% CI: 1.00-1.00); for patients mutated both at T0 and T1, PFS was 22.2% (95% CI: 6.5-75.4%) and OS was 55.6% (95% CI: 20.4-96.1%).

conclusionEGFR mutation status can be assessed using cfDNA for routine purposes and longitudinal assessment of plasma mutation is an easy approach to monitor the therapeutic response or resistance onset.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell-Free Nucleic AcidsDNA Mutational AnalysisDNA, NeoplasmErbB ReceptorsFemaleHumansItalyLiquid BiopsyLung NeoplasmsMaleMiddle AgedMutationBiomarkers, TumorCell-Free Nucleic AcidsDNA, NeoplasmEGFR protein, humanErbB ReceptorscfDNAEGFRLiquid biopsyLung cancerTarget therapy

Identifiers

PMID34003366
PMCPMC8236477
OpenAlexW3163448491

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.